Hindawi Publishing Corporation
PPAR Research
Volume 2009 (2009), Article ID 607902
doi:10.1155/2009/607902

Review Article

HIV-1 Infection and the PPARDependent Control of Adipose Tissue Physiology

Marta Giralt,1,2 Pere Domingo,³ and Francesc Villarroya1,2

¹Department of Biochemistry and Molecular Biology and Institute of Biomedicine, University of Barcelona, 08028 Barcelona, Spain
²CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, 08028 Barcelona, Spain
³Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain

Correspondence should be addressed to Francesc Villarroya, fvillarroya@ub.edu

Received 5 May 2008; Accepted 23 July 2008

Recommended by Jacqueline Capeau

PPAR is a ligand-dependent master transcription factor controlling adipocyte differentiation as well as multiple biological processes taking place in other cells present in adipose tissue depots such as macrophages. Recent research indicates that HIV-1 infection-related events may alter adipose tissue biology through several mechanisms involving PPAR ranging from direct effects of HIV-1-encoded proteins on adipocytes to the promotion of a proinflammatory environment that interferes with PPAR actions. This effect of HIV-1 on adipose tissue cells can occur even in the absence of direct infection of adipocytes, as soluble HIV-1-encoded proteins such as Vpr may enter cells and inhibit PPAR action. Moreover, repression of PPAR actions may relieve inhibitory pathways of HIV-1 gene transcription, thus enhancing HIV-1 effects in infected cells. HIV-1 infection-mediated interference of PPARdependent pathways in adipocytes and other cells inside adipose depots such as macrophages is likely to create an altered local environment that, after antiretroviral treatment, leads to lipodystrophy in HIV-1-infected and HAART-treated patients.

Copyright © 2009 Marta Giralt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

A complex set of metabolic alterations, preferentially involving adipose tissue, has emerged in recent years in a substantial number of HIV-1-infected patients under highly-active antiretroviral treatment (HAART). This is the so-called HIV-1/HAART-associated lipodystrophy syndrome. Disturbances in adipose tissue of these patients range from lipoatrophy of subcutaneous adipose tissue to visceral adipose accumulation or lipomatosis [1]. Moreover, during recent years, basic research on adipose tissue biology has succeeded in identifying major molecular players in the differentiation and function of adipose tissue. Among them, the peroxisome proliferator-activated receptor γ (PPARγ)subtype of PPARs has emerged as a master transcriptional regulator of adipose cells [2]. Although we are still far from a full understanding of the molecular basis of HIV-1 lipodystrophy, research has been actively undertaken in this area and has examined the role of alterations in PPARγ-dependent pathways in eliciting the syndrome [3, 4]. Regardless of the potential effects of antiretroviral drugs on PPARγ, several recent findings suggest that HIV-1 infection-related events may cause disturbances in the PPARγ-dependent pathways of control of adipose tissue physiopathology, and they are summarized in the present review.

2. Adipose Tissue, HIV-1 Infection, and Lipodystrophy

The concepts concerning the causal basis of HIV-1 associated lipodystrophy have evolved substantially in the last few years. The initial identification of HIV-1 lipodystrophy was coincident with the introduction of drugs from the protease inhibitor family for use in antiretroviral treatment, and these drugs were at first considered to be causative of the syndrome [5]. After it was recognized that patients without protease inhibitor treatment could also develop lipodystrophy, the syndrome was associated with HAART overall. Although several drugs of HAART regimes are known at present to be more prone to induce the appearance of lipodystrophy or of some of their particular features (abdominal fat hypertrophy versus peripheral lipoatrophy) than others [6], no single class of drugs can account for elicitation of the overall syndrome. On the other hand, there have been suggestions that antiretroviral treatment causes lipodystrophy only when acting upon HIV-1-infected patients, and that events related to HIV-1 infection are intrinsically associated with the development of the syndrome. Evidently, there are no data on long-term antiretroviral treatment of non-HIV-1-infected patients that could establish the specific role of HAART independent of the HIV-1 infection, and a single two-week study of nucleotide-analog reverse transcriptase inhibitor treatment of non-infected volunteers indicated the appearance of only a few features of the lipodystrophy syndrome [7].

Some data have indicated that mild alterations of adipose tissue biology are already present in nontreated HIV-1-infected patients [8]. The studies of body composition in the era before HAART reported a disproportionate loss of body fat mass in men with advanced HIV-1 disease or AIDS [9]. This was attributed to the progression towards AIDS-related wasting and associated diseases. However, some data suggested that weight loss and depletion of body fat may precede the progression to AIDS, even in adults with normal CD4+ lymphocyte counts [10]. Further studies confirmed an indirect effect of HIV-1 viremia leading to effects similar to AIDS wasting. Studies by Visnegarwala et al. of HIV-1-infected men with CD4+ lymphocyte counts >200 cells/mm³ suggested that malnutrition due to decreased caloric intake and increased energy demands associated with an active opportunistic infection was not contributing factors in explaining reduced body weight [11]. It was concluded that reduction in fat mass is related to HIV-1 infection itself, independent of the additive effects of opportunistic illnesses. Similar conclusions were obtained from the analysis of dyslipemia. Before the introduction of HAART, the early appearance of hypertriglyceridemia and enhanced lipolysis was observed in HIV-1-infected patients before the onset of overt illness [12, 13]. Recent studies have confirmed that HIV-1 infection-induced changes in lipolysis are unrelated to the further effects of HAART leading to full-blown lipodystrophy [14]. Finally, several rodent models relevant to HIV-1 infection events have shown metabolic disturbances in the absence of any exposure to antiretroviral drugs. For instance, transgenic mice expressing the HIV-1 accessory viral protein R (Vpr) in liver and adipose tissue exhibit altered systemic fat metabolism [15]. Disturbances of PPARγ, as a master regulator of adipose tissue differentiation and function, may play a major role in the alterations of adipose mass and lipid metabolism elicited by HIV-1 infection, and this issue is summarized in the present review.

3. PPARγ and Its Pivotal Role in Adipose Tissue Function

PPARγ is highly expressed in adipose tissue, where it plays a key role in adipose tissue development and function. There are two major splice variants of PPARγ, γ1 and γ2, which differ in their N-terminal region (PPARγ2 contains an additional 30 amino acids) and in their tissue-specific expression; PPARγ2 is found almost exclusively in white and brown adipose tissues whereas PPARγ1 is also relatively abundant in macrophages and endothelial cells [16–18]. The activity of both isoforms is regulated by posttranscriptional modifications and by ligand-dependent transactivation and recruitment of coactivators. For instance, phosphorylation inhibits the transcriptional activity of PPARγ [19] and promotes sumoylation, which further reduces its transcriptional activity [20]. PPARγ forms heterodimers with retinoid X receptors (RXRs) to bind to specific DNA sequences in its target genes. In the absence of ligands, corepressors such as nuclear receptor corepressor (N-CoR) or silencing mediator of retinoid and thyroid (SMRT) receptors bind to these heterodimers and recruit histone deacetylases to repress transcription (reviewed in [21]). Binding of ligands to PPARγ triggers conformational changes that allow the recruitment of transcriptional coactivators, including members of the steroid receptor coactivator (SRC) family [22] and PPARγ-coactivator 1α (PGC-1α) [23] that ultimately recruit histone acetyltransferase coactivators such as p300/CBP or PCAF [21].

However, the natural ligands for PPARγ remain unknown. Recent studies have provided functional evidence for an unidentified natural ligand that is produced transiently during adipogenesis [24]. There is also evidence that small lipophilic compounds, such as polyunsaturated fatty acids and fatty acid derivatives (eiocosanoids) bind and activate this receptor [25], thus supporting the concept that PPARγ is a nutrient sensor that finely regulates metabolic homoeostasis in response to different nutritional states.

Regarding synthetic ligands, it is clear that members of the thiazolidinedione (TZD) family of antidiabetic drugs are high-affinity agonists for PPARγ [26]. TZDs have been reported to enhance insulin sensitivity in animals and humans [27]. Furthermore, cellular, genetic, and pharmacological studies have provided strong evidence both that TZDs function via PPARγ, and that adipose tissue is the main site where the insulin-sensitizing effects of PPARγ are produced (reviewed in [28]).

It was reported that TZDs induce adipocyte differentiation even before they were known to be ligands of PPARγ [29]. By now, the key role of PPARγ as a master regulator of adipogenesis has been clearly established, and gain-of-function experiments have demonstrated that PPARγ is sufficient to induce adipocyte differentiation in the presence of an appropriate ligand [30]. However, loss-of-function experiments to prove that PPARγ is required for this process have been more difficult, since PPARγ homozygous inactivation results in embryonic death due to placental alteration, in a developmental stage before there is any adipose tissue development [31]. Later, however, studies utilizing chimeric mice [32] and adipose-specific PPARγ knockout mice [33] confirmed the essential role of PPARγ in adipose tissue differentiation.

PPARγ also plays an important role in regulation of lipid metabolism in mature adipocytes. Activation of PPARγ increases both fatty acid uptake and its storage into adipocytes by promoting the transcription of genes such as those encoding lipoprotein lipase, fatty acid binding protein-4 (aP2/FABP4), phosphoenolpyruvate carboxykinase (PEPCK) [34–37], and also glucose transporter GLUT-4, in order to increase fatty acid synthesis [38]. These effects of PPARγ may underlie its insulin-sensitizing effects. Thus, together with the proadipogenic role of PPARγ (glucose homeostasis requires adequate amounts of adipose tissue), the improvement of lipid storage in this tissue will prevent ectopic lipid accumulation in nonadipose tissues such as liver, skeletal muscle, and β-cells. Furthermore, PPARγ has been reported to induce transcription of the PGC-1α gene in adipose tissue [39]. The coactivator PGC-1α promotes mitochondrial biogenesis, thus leading to an increase in fatty acid oxidation in adipose tissue, which may protect against adipocyte hypertrophy [40]. Finally, adipose tissue has endocrine functions, and PPARγ regulates expression of genes encoding adipokines such as adiponectin, leptin, resistin, or cytokines such as TNFα. Activation of PPARγ promotes the expression of a pro-insulin-sensitizing adipokine profile (i.e., induction of adiponectin and reduction of TNFα gene expression) thus involving the cross-talk between adipose tissue and other insulin-sensitive organs (liver, skeletal muscle) in the insulin-sensitizing effects of PPARγ [41].

Evidence from human mutations in PPARγ has further underlined the importance of PPARγ in the development of adipose tissue, in the maintenance of glucose and lipid homeostasis and more generally in the control of energy balance (reviewed in [42]). Patients harboring mutations in the ligand-binding domain of PPARγ have a stereotyped phenotype characterized by partial lipodystrophy, severe insulin resistance, dyslipidemia, hepatic steatosis, and hypertension, thus identifying PPARγ as playing a molecular role in the pathogenesis of the metabolic syndrome [43, 44].

PPARγ is also expressed in macrophages and endothelial cells, that is, cells that are present in adipose tissue [17, 18, 45]. In endothelial cells, activation of PPARγ has antiproliferative, antiangiogenic, and anti-inflammatory effects [45]. PPARγ is induced during macrophage differentiation, and its activation increases the expression of macrophage-specific markers, such as CD14 and CD11b [17, 46]. However, loss-of-function approaches have demonstrated that PPARγ is not essential for monocyte/macrophage differentiation either in vivo or in vitro [47, 48] but selective deletion of PPARγ in macrophages results in increased insulin resistance [49]. Recently, macrophage-mediated inflammation in adipose tissue has been proposed to play a central role in the pathogenesis of insulin resistance [50]. Two types of macrophages, proinflammatory M1 and anti-inflammatory M2, are present in adipose tissue and their relative abundance may change dynamically through recruitment of polarized monocytes from the blood (macrophage infiltration) or through the effects of local cytokines on macrophages in adipose tissue. Activation of PPARγ by TZDs has now been reported to increase the proportion of anti-inflammatory M2 macrophages in adipose tissue [51]. Furthermore, TZDs also act through PPARγ to inhibit the expression of inflammatory mediators in macrophages, and as reported above, to negatively regulate expression of cytokines such as IL-6, TNF-α, and monocyte chemoattractant protein—1 (MCP-1/CCL-2) in adipocytes [52]. In summary, activation of PPARγ improves adipose tissue function by having a beneficial effect on the adipocyte—macrophage relationship, which may result in prevention of insulin resistance.

4. HIV-1 Infection and PPARγ

Recent studies revealed that expression of marker genes of adipogenesis, such as those encoding GLUT-4, adiponectin, or lipoprotein lipase is already altered in subcutaneous adipose tissue from HIV-1-infected patients in the absence of treatment [53]. These genes are known targets of PPARγ, and the expression of PPARγ itself is also reduced in HIV-1-infected patients without treatment, relative to healthy controls [53]. In fact, in this same sense, it has been observed that PPARγ expression is lower in HIV-1-infected and HAART-treated patients with lipodystrophy relative to healthy controls [54], but similar when compared to levels in antiretroviral-naive patients [55]. These findings point to the possibility that HIV-1 infection and associated events interfere with the action of PPARγ as a master transcriptional controller of adipogenesis and, in a broader sense, of adipose tissue biology, thus contributing to the appearance of lipodystrophy. Recent experimental evidence is supportive of this possibility (see below). However, a relevant role of HAART in worsening potential HIV-1-mediated alterations in PPARγ expression cannot be excluded. In this sense, it has been recently reported that a 6-month interruption of antiretroviral treatment results in a significant amelioration of PPARγ levels in patients formerly under HAART containing protease inhibitors [56]. On the other hand, one of the features of HIV-1-associated lipodystrophy is insulin resistance. It cannot be excluded that PPARγ impairment in HIV-1-infected patients may contribute to reduced insulin sensitivity, as PPARγ is a known target of drugs with insulin-sensitizing properties (see above).

It must be taken into account that the action of HIV-1 infection in adipose tissue and PPARγ activity should not be considered only in relation to adipocytes. As stated above, adipose tissue depots contain, in addition to adipocytes, other cells such as preadipocytes, macrophages, or endothelial cells. Recently, even lymphocytes have been reported to be present inside adipose depots [57, 58]. As these other cell types (e.g., macrophages or endothelial cells) also express PPARγ, they could themselves be sensitive to HIV-1-mediated disturbances in PPARγ expression and activity. Moreover, cells inside adipose tissue can release regulatory factors (such as adipokines or cytokines) or metabolites (free fatty acids) capable of influencing surrounding cells, for instance preadipocytes and adipocytes, and the overall pathways of gene regulation dependent on PPARγ.

5. How May HIV-1 Infection Affect PPARγ Pathways in Adipose Tissue?

The possibility that HIV-1 infection could influence PPARγ activity leads to the first consideration; whether the cells present in adipose tissue depots can be infected by HIV-1. The capacity of HIV-1 to infect adipocytes is controversial. Whereas some initial reports indicated that adipocytes could be infected [59, 60], later data appeared to exclude this possibility [61]. However, more recently, it was reported that substantial infection of adipocytes could take place when TNFα was present in the medium [62]. High levels of TNFα are found in adipose tissue from HIV-1-infected patients even before treatment and are part of a proinflammatory environment already present in adipose tissue as a consequence of long-term HIV-1 infection [53, 63]. It should be noted that studies on the capacity of HIV-1 to infect adipose cells have focused on mature adipocytes and less is known concerning preadipocytes. In adipose depots, resident preadipocytes are found and they can differentiate into mature adipocytes. Lipoatrophic situations combine a loss of adipose cells (primarily via apoptosis) and an incapacity of preadipocytes to differentiate and replenish the depot; thus any direct or indirect effect of HIV-1 infection that interferes with PPARγ could lead to this impaired differentiation. Recent identification of PPARγ gene mutations causative of lipodystrophies of genetic origin supports the notion that abnormal PPARγ function can lead to lipodystrophy [42, 64].

Evidently, if a cell of the adipocyte lineage is infected by HIV-1, it will be exposed to gene products of HIV-1 and to their potential effects on PPARγ actions. A reported example of this is Nef, a 27 kDa HIV-1-encoded protein that localizes in the cytoplasm as well as nucleus of infected cells [65]. It has been shown that nuclear Nef results in a reduction in the expression of PPARγ and of PPARγ gene targets in human T cells and macrophages as well as interfering with fat accumulation in cell lines [66]. The effects of Nef were specific in impairing PPARγ-dependent, but not PPARα-dependent, transcriptional activity.

However, the most relevant evidence of interference of PPARγ pathways by HIV-1-encoded products concerns the HIV-1 accessory protein Vpr. Kopp and collaborators have recently shown that Vpr suppresses the differentiation of adipocytes in cell culture by interfering with PPARγ-dependent transactivation of target genes [67]. Vpr acts as a corepressor of PPARγ by interacting with the ligand-binding domain of the receptor in an agonist-dependent manner. Remarkably, this effect could be observed when Vpr was added to the adipose cell culture media thus indicating that, as already shown in other cell types [68], exogenous Vpr can enter the cell and interfere with metabolic pathways. These findings are highly relevant to an understanding of the etiopathogenesis of lipodystrophy in HIV-1-infected patients. Thus, it is expected that adipose cells can be affected by Vpr either due to direct infection by HIV-1, or indirectly, because Vpr is known to be present as a soluble protein in the circulation of HIV-1 infected patients [69]. Moreover, adipocytes and preadipocytes may be exposed to local concentrations of Vpr higher than those in the overall circulation, given the proximity of cells such as macrophages (or even resident lymphocytes) that can be infected and release Vpr.

Finally, recent research has revealed several features of the biology of PPARγ, in relation to adipogenesis, in which HIV-1 infection may be hypothesized to interfere. Thus, several players in cell cycle control, such as cyclin D3 and CDK4, have been reported to promote adipogenesis through interaction with PPARγ [70, 71], whereas E2F4 represses PPARγ during adipogenesis [72]. HIV-1 infection may interfere with the cell cycle machinery, and specifically the HIV-1-encoded proteins Vpr and Tat have been recognized as being capable of interacting with CDK4, cyclin D3, and E2F4 [73–75]. However, the capacity of these interactions to influence PPARγ-dependent pathways in adipocytes or in other cells present in adipose depots, and their consequences for metabolism, remains to be explored. Similarly, a number of reports have indicated that HIV-1-encoded Tat or Vpr can interact with known coactivators of PPARγ required for its transcriptional activity, such as p300/CBP or PCAF [76, 77]. It cannot be excluded that HIV-1 infection-mediated events affect PPARγ activity in adipose tissue through these interactions, although experimental evidence for this is lacking at present.

6. The Reciprocal Issue: the Effect of PPARγ on HIV-1 Biology, and the Implications of This for Adipose Tissue Pathophysiology

What we have described up to now provides evidence that HIV-1 infection may alter PPARγ activities. However, several reports also indicate the occurrence of reciprocal events, that is, the action of PPARs and particularly PPARγ on HIV-1 biology, especially on the replication and transcription of the HIV-1 genome. The capacity of nuclear receptors to interact with the long-terminal repeat of HIV-1 was recognized several years ago [78]. It was observed that heterodimers of RXR and PPARα were capable of binding a region between −356 to −320 in the long terminal repeat. Accordingly, PPARα agonists such as clofibric acid were shown to activate HIV-1 transcription [79]. This effect, which may be relevant in tissues such as liver which express high levels of PPARα, is not expected to be involved in alterations of white adipocytes and preadipocytes which are almost devoid of PPARα [80].

In contrast, it was reported recently that the PPARγ agonist ciglitazone inhibits HIV-1 replication in a dose-dependent manner in acutely-infected human monocyte-derived macrophages and in latently-infected and viral entry-independent U1 cells, suggesting an effect at the level of HIV-1 gene expression [81]. Cotransfection of PPARγ wild-type vectors and treatment with PPARγ agonists inhibited HIV-1 promoter activity in U937 cells, and activation of PPARγ also decreased HIV-1 mRNA stability following actinomycin D treatment. Thus, natural and synthetic PPARγ agonists may play a role in controlling HIV-1 infection in macrophages [81, 82]. Similar observations were obtained by Skolnik et al. who observed that activation of PPARγ, and also of PPARα, by specific agonists also decreased HIV-1 replication in peripheral blood mononuclear cells acutely infected with HIV-1, in a chronically-infected monoblastoid cell line and in alveolar macrophages from HIV-1-infected subjects and uninfected controls [83]. The precise mechanisms of action of PPARγ on HIV-1 are not fully known and, in addition to the potential direct interaction with specific regions of the long-terminal repeat mentioned above, indirect effects via nuclear factor κB have also been proposed on the basis of the effects of PPARγ and its ligand rosiglitazone impairing nuclear factor κB-mediated enhancement of HIV-1 replication in macrophages [84].

All these findings indicate the occurrence of a potential cross-talk between PPARγ and HIV-1 that could reinforce the activity of HIV-1 proteins in cells harboring PPARγ. Thus, a reduction in PPARγ levels and/or activity as a consequence of HIV-1 infection may lead to depression of such a pathway of potential inhibition of HIV-1 transcription and could create an environment prone to enhancement of HIV-1 gene expression, establishing a “vicious cycle” further augmenting adipose pathogenesis.

7. Conclusions

In summary, research to date indicates that HIV-1 infection-related events may alter adipose tissue and contribute to development of the full-blown lipodystrophy syndrome after antiretroviral treatment. The role of HIV-1 infection of cells in adipose tissue, of soluble proteins released by infected cells as well as of the indirect effects elicited by the mild proinflammatory environment associated with viral infection, is issues expected to be the subject of intense research in the near future. For all these aspects, PPARγ appears as a main candidate for the mediation of pathogenic events. Moreover, a full understanding will be required of the relationships among the complex set of cell types that, in addition to adipocytes, are present in adipose tissue depots. Macrophages, endothelial cells, preadipocytes, and perhaps even lymphocytes are present in adipose depots and establish a complex regulatory cross-talk that is altered by HIV-1 infection, and which may ultimately lead to disturbances in adipocytes and in the whole adipose mass (see Figure 1). All of these cell types express PPARγ, and the pivotal role of this receptor in adipogenesis, insulin sensitivity, lipid metabolism, and inflammatory pathways point to this receptor as a key target of future research on adipose tissue disturbances in the HIV-1/HAART-associated lipodystrophy syndrome.

Figure 1: Schematic representation of the potential effects of HIV-1 infection on PPARγ-mediated pathways in adipocytes and macrophages. HIV-1 infection of macrophages may lead to the synthesis of HIV-1 encoded proteins, that is, Vpr, with negative effects on the expression of PPARγ target genes. This may lead to reduced expression of anti-inflammatory genes as well as promotion of HIV-1 replication. Release of HIV-1-encoded proteins as well as enhanced production of inflammatory cytokines, that is, TNFα and other, by macrophages as a consequence of HIV-1 infection may lead to impaired PPARγ action in adipocytes and preadipocytes, thus impairing adipogenesis and fat accretion. Direct effects of HIV-1 infection in line with what happens in macrophages cannot be excluded. Similar events to those depicted for macrophages could be considered to occur in endothelial cells or even lymphocytes present in adipose tissue depots as a consequence of HIV-1 infection.

Acknowledgments

This work was supported by grants from Ministerio de Educación y Ciencia (SAF2005-01722), Fondo de Investigaciones Sanitarias (PI052336) and ISCIII-RETIC RD06/006, Ministerio de Sanidad y Consumo, and FIPSE (36752/06, 36610/06), Spain .

References

S. Grinspoon and A. Carr, “Cardiovascular risk and body-fat abnormalities in HIV-infected adults,” The New England Journal of Medicine, vol. 352, no. 1, pp. 48–62, 2005.

E. D. Rosen, C. J. Walkey, P. Puigserver, and B. M. Spiegelman, “Transcriptional regulation of adipogenesis,” Genes & Development, vol. 14, no. 11, pp. 1293–1307, 2000.

M.-L. Gougeon, L. Pénicaud, B. Fromenty, P. Leclercq, J.-P. Viard, and J. Capeau, “Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations,” Antiviral Therapy, vol. 9, no. 2, pp. 161–177, 2004.

F. Villarroya, P. Domingo, and M. Giralt, “Lipodystrophy in HIV 1-infected patients: lessons for obesity research,” International Journal of Obesity, vol. 31, no. 12, pp. 1763–1776, 2007.

A. Carr, K. Samaras, D. J. Chisholm, and D. A. Cooper, “Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance,” The Lancet, vol. 351, no. 9119, pp. 1881–1883, 1998.

D. Nolan, M. John, and S. Mallal, “Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis,” Antiviral Therapy, vol. 6, no. 3, pp. 145–160, 2001.

P. W. G. Mallon, P. Unemori, R. Sedwell, et al., “In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA,” Journal of Infectious Diseases, vol. 191, no. 10, pp. 1686–1696, 2005.

J. Miller, A. Carr, S. Emery, et al., “HIV lipodystrophy: prevalence, severity and correlates of risk in Australia,” HIV Medicine, vol. 4, no. 3, pp. 293–301, 2003.

D. P. Kotler, J. Wang, and R. N. Pierson Jr., “Body composition studies in patients with the acquired immunodeficiency syndrome,” American Journal of Clinical Nutrition, vol. 42, no. 6, pp. 1255–1265, 1985.

M. Ott, B. Lembcke, H. Fischer, et al., “Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition,” American Journal of Clinical Nutrition, vol. 57, no. 1, pp. 15–19, 1993.

F. Visnegarwala, S. S. Raghavan, C. M. Mullin, et al., “Sex differences in the associations of HIV disease characteristics and body composition in antiretroviral-naive persons,” American Journal of Clinical Nutrition, vol. 82, no. 4, pp. 850–856, 2005.

C. Grunfeld, D. P. Kotler, R. Hamadeh, A. Tierney, J. Wang, and R. N. Pierson Jr., “Hypertriglyceridemia in acquired immunodeficiency syndrome,” The American Journal of Medicine, vol. 86, no. 1, pp. 27–31, 1989.

M. D. Peck, E. Mantero-Atienza, M. J. Miguez-Burbano, et al., “The esterified plasma fatty acid profile is altered in early HIV-1 infection,” Lipids, vol. 28, no. 7, pp. 593–597, 1993.

M. van der Valk, P. Reiss, F. C. van Leth, et al., “Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 11, pp. 5066–5071, 2002.

A. Balasubramanyam, H. Mersmann, F. Jahoor, et al., “Effects of transgenic expression of HIV-1 Vpr on lipid and energy metabolism in mice,” American Journal of Physiology, vol. 292, no. 1, pp. E40–E48, 2007.

A. J. Vidal-Puig, R. V. Considine, M. Jimenez-Liñan, et al., “Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids,” The Journal of Clinical Investigation, vol. 99, no. 10, pp. 2416–2422, 1997.

M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.

N. Marx, T. Bourcier, G. K. Sukhova, P. Libby, and J. Plutzky, “PPAR activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR as a potential mediator in vascular disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 3, pp. 546–551, 1999.

E. Hu, J. B. Kim, P. Sarraf, and B. M. Spiegelman, “Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR,” Science, vol. 274, no. 5295, pp. 2100–2103, 1996.

D. Yamashita, T. Yamaguchi, M. Shimizu, N. Nakata, F. Hirose, and T. Osumi, “The transactivating function of peroxisome proliferator-activated receptor is negatively regulated by SUMO conjugation in the amino-terminal domain,” Genes to Cells, vol. 9, no. 11, pp. 1017–1029, 2004.

E. Powell, P. Kuhn, and W. Xu, “Nuclear receptor cofactors in PPARmediated adipogenesis and adipocyte energy metabolism,” PPAR Research, vol. 2007, Article ID 53843, 11 pages, 2007.

N. J. McKenna and B. W. O'Malley, “Combinatorial control of gene expression by nuclear receptors and coregulators,” Cell, vol. 108, no. 4, pp. 465–474, 2002.

P. Puigserver, Z. Wu, C. W. Park, R. Graves, M. Wright, and B. M. Spiegelman, “A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis,” Cell, vol. 92, no. 6, pp. 829–839, 1998.

I. Tzameli, H. Fang, M. Ollero, et al., “Regulated production of a peroxisome proliferator-activated receptor- ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes,” The Journal of Biological Chemistry, vol. 279, no. 34, pp. 36093–36102, 2004.

B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-prostaglandin is a ligand for the adipocyte determination factor PPAR,” Cell, vol. 83, no. 5, pp. 803–812, 1995.

J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995.

J. M. Olefsky and A. R. Saltiel, “PPAR and the treatment of insulin resistance,” Trends in Endocrinology and Metabolism, vol. 11, no. 9, pp. 362–368, 2000.

C. Knouff and J. Auwerx, “Peroxisome proliferator-activated receptor- calls for activation in moderation: lessons from genetics and pharmacology,” Endocrine Reviews, vol. 25, no. 6, pp. 899–918, 2004.

R. F. Kletzien, S. D. Clarke, and R. G. Ulrich, “Enhancement of adipocyte differentiation by an insulin-sensitizing agent,” Molecular Pharmacology, vol. 41, no. 2, pp. 393–398, 1992.

P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPAR2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994.

Y. Barak, M. C. Nelson, E. S. Ong, et al., “PPAR is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999.

E. D. Rosen, P. Sarraf, A. E. Troy, et al., “PPAR is required for the differentiation of adipose tissue in vivo and in vitro,” Molecular Cell, vol. 4, no. 4, pp. 611–617, 1999.

W. He, Y. Barak, A. Hevener, et al., “Adipose-specific peroxisome proliferator-activated receptor knockout causes insulin resistance in fat and liver but not in muscle,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15712–15717, 2003.

K. Schoonjans, J. Peinado-Onsurbe, A.-M. Lefebvre, et al., “PPAR and PPAR activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” The EMBO Journal, vol. 15, no. 19, pp. 5336–5348, 1996.

P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPAR2: tissue-specific regulator of an adipocyte enhancer,” Genes & Development, vol. 8, no. 10, pp. 1224–1234, 1994.

P. Tontonoz, E. Hu, J. Devine, E. G. Beale, and B. M. Spiegelman, “PPAR2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene,” Molecular and Cellular Biology, vol. 15, no. 1, pp. 351–357, 1995.

Y. Olswang, H. Cohen, O. Papo, et al., “A mutation in the peroxisome proliferator-activated receptor binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 2, pp. 625–630, 2002.

Z. Wu, Y. Xie, R. F. Morrison, N. L. R. Bucher, and S. R. Farmer, “PPAR induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBP during the conversion of 3T3 fibroblasts into adipocytes,” The Journal of Clinical Investigation, vol. 101, no. 1, pp. 22–32, 1998.

E. Hondares, O. Mora, P. Yubero, et al., “Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1 gene transcription: an autoregulatory loop controls PGC-1 expression in adipocytes via peroxisome proliferator-activated receptor- coactivation,” Endocrinology, vol. 147, no. 6, pp. 2829–2838, 2006.

L. Wilson-Fritch, A. Burkart, G. Bell, et al., “Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone,” Molecular and Cellular Biology, vol. 23, no. 3, pp. 1085–1094, 2003.

S. M. Rangwala and M. A. Lazar, “Peroxisome proliferator-activated receptor in diabetes and metabolism,” Trends in Pharmacological Sciences, vol. 25, no. 6, pp. 331–336, 2004.

R. K. Semple, V. K. K. Chatterjee, and S. O'Rahilly, “PPAR and human metabolic disease,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 581–589, 2006.

I. Barroso, M. Gurnell, V. E. F. Crowley, et al., “Dominant negative mutations in human PPAR associated with severe insulin resistance, diabetes mellitus and hypertension,” Nature, vol. 402, no. 6764, pp. 880–883, 1999.

D. B. Savage, G. D. Tan, C. L. Acerini, et al., “Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-,” Diabetes, vol. 52, no. 4, pp. 910–917, 2003.

L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” Pharmacology & Therapeutics, vol. 110, no. 3, pp. 371–385, 2006.

P. Tontonoz, L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans, “PPAR promotes monocyte/macrophage differentiation and uptake of oxidized LDL,” Cell, vol. 93, no. 2, pp. 241–252, 1998.

A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, “PPAR- dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation,” Nature Medicine, vol. 7, no. 1, pp. 48–52, 2001.

K. J. Moore, E. D. Rosen, M. L. Fitzgerald, et al., “The role of PPAR- in macrophage differentiation and cholesterol uptake,” Nature Medicine, vol. 7, no. 1, pp. 41–47, 2001.

A. Chawla, W. A. Boisvert, C.-H. Lee, et al., “A PPARLXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis,” Molecular Cell, vol. 7, no. 1, pp. 161–171, 2001.

S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” The Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006.

J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth, et al., “Macrophage-specific PPAR controls alternative activation and improves insulin resistance,” Nature, vol. 447, no. 7148, pp. 1116–1120, 2007.

A. M. Sharma and B. Staels, “Peroxisome proliferator-activated receptor and adipose tissue—understanding obesity-related changes in regulation of lipid and glucose metabolism,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 2, pp. 386–395, 2007.

M. Giralt, P. Domingo, J. P. Guallar, et al., “HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy,” Antiviral Therapy, vol. 11, no. 6, pp. 729–740, 2006.

J.-P. Bastard, M. Caron, H. Vidal, et al., “Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance,” The Lancet, vol. 359, no. 9311, pp. 1026–1031, 2002.

C. S. Pace, A. M. Martin, E. L. Hammond, C. D. Mamotte, D. A. Nolan, and S. A. Mallal, “Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients,” Antiviral Therapy, vol. 8, no. 4, pp. 323–331, 2003.

J. K. Min, P. Leclercq, E. Lanoy, et al., “A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study,” Antiviral Therapy, vol. 12, no. 8, pp. 1273–1283, 2007.

S. Caspar-Bauguil, B. Cousin, A. Galinier, et al., “Adipose tissues as an ancestral immune organ: site-specific change in obesity,” FEBS Letters, vol. 579, no. 17, pp. 3487–3492, 2005.

H. Wu, S. Ghosh, X. D. Perrard, et al., “T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity,” Circulation, vol. 115, no. 8, pp. 1029–1038, 2007.

U. Hazan, I. A. Romero, R. Cancello, et al., “Human adipose cells express CD4, CXCR4, and CCR5 receptors: a new target cell type for the immunodeficiency virus-1?” The FASEB Journal, vol. 16, no. 10, pp. 1254–1256, 2002.

N. Dupin, M. Buffet, A.-G. Marcelin, et al., “HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy,” AIDS, vol. 16, no. 18, pp. 2419–2424, 2002.

S. Munier, A. Borjabad, M. Lemaire, V. Mariot, and U. Hazan, “In vitro infection of human primary adipose cells with HIV-1: a reassessment,” AIDS, vol. 17, no. 17, pp. 2537–2539, 2003.

T. Maurin, C. Saillan-Barreau, B. Cousin, L. Casteilla, A. Doglio, and L. Pénicaud, “Tumor necrosis factor- stimulates HIV-1 production in primary culture of human adipocytes,” Experimental Cell Research, vol. 304, no. 2, pp. 544–551, 2005.

J. A. Johnson, J. B. Albu, E. S. Engelson, et al., “Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy,” American Journal of Physiology, vol. 286, no. 2, pp. E261–E271, 2004.

R. A. Hegele, “Lessons from human mutations in PPAR,” International Journal of Obesity, vol. 29, supplement 1, pp. S31–S35, 2005.

K. G. Murti, P. S. Brown, L. Ratner, and J. V. Garcia, “Highly localized tracks of human immunodeficiency virus type 1 Nef in the nucleus of cells of a human T-cell line,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 11895–11899, 1993.

K. Otake, S. Omoto, T. Yamamoto, et al., “HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors,” AIDS, vol. 18, no. 2, pp. 189–198, 2004.

S. Shrivastav, T. Kino, T. Cunningham, et al., “Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy,” Molecular Endocrinology, vol. 22, no. 2, pp. 234–247, 2008.

P. Henklein, K. Bruns, M. P. Sherman, et al., “Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces cell cycle arrest,” The Journal of Biological Chemistry, vol. 275, no. 41, pp. 32016–32026, 2000.

D. N. Levy, Y. Refaeli, R. R. MacGregor, and D. B. Weiner, “Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 23, pp. 10873–10877, 1994.

D. A. Sarruf, I. Iankova, A. Abella, S. Assou, S. Miard, and L. Fajas, “Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor ,” Molecular and Cellular Biology, vol. 25, no. 22, pp. 9985–9995, 2005.

A. Abella, P. Dubus, M. Malumbres, et al., “Cdk4 promotes adipogenesis through PPAR activation,” Cell Metabolism, vol. 2, no. 4, pp. 239–249, 2005.

L. Fajas, R. L. Landsberg, Y. Huss-Garcia, C. Sardet, J. A. Lees, and J. Auwerx, “E2Fs regulate adipocyte differentiation,” Developmental Cell, vol. 3, no. 1, pp. 39–49, 2002.

C. Ambrosino, C. Palmieri, A. Puca, et al., “Physical and functional interaction of HIV-1 Tat with E2F-4, a transcriptional regulator of mammalian cell cycle,” The Journal of Biological Chemistry, vol. 277, no. 35, pp. 31448–31458, 2002.

S. Amini, K. Khalili, and B. E. Sawaya, “Effect of HIV-1 Vpr on cell cycle regulators,” DNA and Cell Biology, vol. 23, no. 4, pp. 249–260, 2004.

B. Y. Zhou and J. J. He, “Proliferation inhibition of astrocytes, neurons, and non-glial cells by intracellularly expressed human immunodeficiency virus type 1 (HIV-1) Tat protein,” Neuroscience Letters, vol. 359, no. 3, pp. 155–158, 2004.

G. Marzio, M. Tyagi, M. I. Gutierrez, and M. Giacca, “HIV-1 Tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 23, pp. 13519–13524, 1998.

T. Kino, A. Gragerov, O. Slobodskaya, M. Tsopanomichalou, G. P. Chrousos, and G. N. Pavlakis, “Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators,” Journal of Virology, vol. 76, no. 19, pp. 9724–9734, 2002.

V. Desai-Yajnik, E. Hadzic, P. Modlinger, S. Malhotra, G. Gechlik, and H. H. Samuels, “Interactions of thyroid hormone receptor with the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and the HIV-1 Tat transactivator,” Journal of Virology, vol. 69, no. 8, pp. 5103–5112, 1995.

J. A. A. Ladias, “Convergence of multiple nuclear receptor signaling pathways onto the long terminal repeat of human immunodeficiency virus-1,” The Journal of Biological Chemistry, vol. 269, no. 8, pp. 5944–5951, 1994.

I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.

M. M. Hayes, B. R. Lane, S. R. King, D. M. Markovitz, and M. J. Coffey, “Peroxisome proliferator-activated receptor agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects,” The Journal of Biological Chemistry, vol. 277, no. 19, pp. 16913–16919, 2002.

S. M. Wahl, T. Greenwell-Wild, G. Peng, G. Ma, J. M. Orenstein, and N. Vázquez, “Viral and host cofactors facilitate HIV-1 replication in macrophages,” Journal of Leukocyte Biology, vol. 74, no. 5, pp. 726–735, 2003.

P. R. Skolnik, M. F. Rabbi, J.-M. Mathys, and A. S. Greenberg, “Stimulation of peroxisome proliferator-activated receptors and blocks HIV-1 replication and TNF production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects,” Journal of Acquired Immune Deficiency Syndromes, vol. 31, no. 1, pp. 1–10, 2002.

R. Potula, S. H. Ramirez, B. Knipe, et al., “Peroxisome proliferator-receptor agonist suppresses HIV-1 replication by inhibition of the nuclear factor B in vitro and in an animal model of HIV-1 encephalitis,” Journal of NeuroVirology, vol. 12, supplement 1, p. 66, 2006.